Polar Capital Holdings Plc
Position in DNTH — Dianthus Therapeutics, Inc. /DE/
CIK 1837309
London, X0
Position in DNTH
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$99,305,410
+$9,006,735 QoQ
Shares Held
1,018,726
-5.3% QoQ
Ownership
1.82%
of shares outstanding
% of Portfolio
0.28%
of 13F equity value
Holder Rank
#18
of 269 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNTH Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Polar Capital Holdings Plc holds $3,774,805,029 across 41 Biotechnology names. DNTH ranks #15 (2.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ELVN |
Enliven Therapeutics, Inc.
|
6,430,636 | $326,354,777 | |
| 2 | XENE |
Xenon Pharmaceuticals Inc.
|
4,570,556 | $275,878,760 | |
| 3 | CYTK |
Cytokinetics Inc
|
2,253,649 | $191,988,358 | |
| 4 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
1,663,632 | $184,713,060 | |
| 5 | ARQT |
Arcutis Biotherapeutics, Inc.
|
6,606,945 | $173,234,097 | |
| 6 | ASND |
Ascendis Pharma A/S
|
616,908 | $164,541,701 | |
| 7 | BBIO |
BridgeBio Pharma, Inc.
|
2,063,609 | $153,697,598 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
482,751 | $145,322,533 |
All Filings in DNTH
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $99,305,410 | 1,018,726 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $90,298,675 | 1,076,009 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $41,404,840 | 1,004,728 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $29,433,918 | 748,003 | Shares | Defined | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||